Login to Your Account



CEO Rosconi Takes Final Bow

Theratechnologies Shares Leap on FDA OK of Egrifta

By Donna Young


Friday, November 12, 2010
WASHINGTON – Shares of Theratechnologies Inc. soared as high as 23 percent Thursday on word that the Canadian biotech won U.S. approval of Egrifta (tesamorelin) as the first and only therapy for HIV-associated lipodystrophy, a metabolic complication that affects patients taking antiretroviral therapies long term. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription